Proprietary AAV capsids to power second-generation efforts in Huntington’s disease and ALS, pre-clinical programs in spinal muscular atrophy and diseases linked to GBA1 mutations Increased platform investment to expand discovery of novel targeted AAV capsids and clinical application of vectorized

Reader Interactions

Leave A Reply